Paul Tudor Jones's JAZZ Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 29,725 shares of Jazz Pharmaceuticals plc (JAZZ) worth $5.05 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in JAZZ, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 49,144 shares. Largest reduction occurred in Q2 2020, reducing 33,198 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Jazz Pharmaceuticals plc (JAZZ) Holding Value Over Time
Track share changes against reported price movement
Quarterly Jazz Pharmaceuticals plc (JAZZ) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +29,725 | New Buy | 29,725 | $170.00 |
| Q2 2025 | -8,749 | Sold Out | 0 | $0.00 |
| Q1 2025 | +8,749 | New Buy | 8,749 | $124.15 |
| Q2 2024 | -25,702 | Sold Out | 0 | $0.00 |
| Q1 2024 | -7,256 | Reduce 22.02% | 25,702 | $120.42 |
| Q4 2023 | +24,814 | Add 304.69% | 32,958 | $123.00 |
| Q3 2023 | -9,909 | Reduce 54.89% | 8,144 | $129.44 |
| Q2 2023 | +18,053 | New Buy | 18,053 | $123.97 |
| Q1 2023 | -23,795 | Sold Out | 0 | $0.00 |
| Q4 2022 | -1,244 | Reduce 4.97% | 23,795 | $0.16 |
| Q3 2022 | -5,529 | Reduce 18.09% | 25,039 | $133.27 |
| Q2 2022 | +23,092 | Add 308.88% | 30,568 | $156.01 |
| Q1 2022 | +3,778 | Add 102.16% | 7,476 | $155.70 |
| Q4 2021 | -7,426 | Reduce 66.76% | 3,698 | $127.37 |
| Q3 2021 | +11,124 | New Buy | 11,124 | $130.17 |
| Q2 2021 | -2,561 | Sold Out | 0 | $0.00 |
| Q1 2021 | +2,561 | New Buy | 2,561 | $164.39 |
| Q3 2020 | -2,654 | Sold Out | 0 | $0.00 |
| Q2 2020 | -33,198 | Reduce 92.60% | 2,654 | $110.40 |
| Q1 2020 | -13,292 | Reduce 27.05% | 35,852 | $99.74 |
| Q4 2019 | +49,144 | New Buy | 49,144 | $149.28 |
| Q3 2019 | -19,380 | Sold Out | 0 | $0.00 |
| Q2 2019 | -77 | Reduce 0.40% | 19,380 | $142.57 |
| Q1 2019 | -2,514 | Reduce 11.44% | 19,457 | $142.93 |
| Q4 2018 | +21,971 | New Buy | 21,971 | $123.98 |
| Q3 2018 | -1,474 | Sold Out | 0 | $0.00 |
| Q2 2018 | +1,474 | New Buy | 1,474 | $172.32 |
| Q1 2018 | -14,313 | Sold Out | 0 | $0.00 |
| Q4 2017 | +14,313 | New Buy | 14,313 | $134.63 |
| Q3 2017 | -4,664 | Sold Out | 0 | $0.00 |
| Q2 2017 | +2,278 | Add 95.47% | 4,664 | $155.45 |
| Q1 2017 | -5,723 | Reduce 70.58% | 2,386 | $145.01 |
| Q4 2016 | -10,048 | Reduce 55.34% | 8,109 | $109.01 |
| Q3 2016 | -8,392 | Reduce 31.61% | 18,157 | $121.50 |
| Q2 2016 | +12,997 | Add 95.90% | 26,549 | $141.32 |
| Q1 2016 | +6,764 | Add 99.65% | 13,552 | $130.53 |
| Q4 2015 | +1,257 | Add 22.73% | 6,788 | $140.54 |
| Q3 2015 | +5,531 | New Buy | 5,531 | $132.89 |
| Q1 2015 | -1,400 | Sold Out | 0 | $0.00 |
| Q4 2014 | -200 | Reduce 12.50% | 1,400 | $163.57 |
| Q3 2014 | +200 | Add 14.29% | 1,600 | $160.62 |
| Q2 2014 | -2,700 | Reduce 65.85% | 1,400 | $147.14 |
| Q1 2014 | +1,163 | Add 39.60% | 4,100 | $138.78 |
| Q4 2013 | -2,563 | Reduce 46.60% | 2,937 | $126.66 |
| Q3 2013 | -2,700 | Reduce 32.93% | 5,500 | $92.00 |
| Q2 2013 | +8,201 | Add 0.00% | 8,200 | $68.78 |
Paul Tudor Jones's Jazz Pharmaceuticals plc Investment FAQs
Paul Tudor Jones first purchased Jazz Pharmaceuticals plc (JAZZ) in Q2 2013, acquiring 8,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Jazz Pharmaceuticals plc (JAZZ) for 46 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Jazz Pharmaceuticals plc (JAZZ) was in Q4 2019, adding 49,144 shares worth $7.34 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 29,725 shares of Jazz Pharmaceuticals plc (JAZZ), valued at approximately $5.05 M.
As of the Q4 2025 filing, Jazz Pharmaceuticals plc (JAZZ) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Jazz Pharmaceuticals plc (JAZZ) was 49,144 shares, as reported at the end of Q4 2019.